In this edition:
2024 vs. 2017 McDonald criteria
Revised 2025 IPND criteria, terminology & classification
ORATORIO-HAND: ocrelizumab in PPMS
GAVOTTE: body-weight-adjusted high-dose vs. standard dose ocrelizumab in PPMS
OPERETTA 2: ocrelizumab vs. fingolimod in paediatric-onset RRMS
CCMR-Two: metformin + clemastine in RRMS
GEMINI 1/2: tolebrutinib vs. teriflunomide in relapsing MS
CALLIPER: vidofludimus calcium in progressive MS
EBV-infected B-cells in MS leptomeninges
Please login below to download this issue (PDF)